Why Alvotech’s Latest Capital Raise Matters For Shareholders

Alvotech (ALVO) has just closed an underwritten public offering and arranged a concurrent private placement, together expected to bring in about $165 million to support its biosimilar portfolio and broader corporate needs.

For existing and prospective shareholders, this new equity funding directly affects ownership dilution, future cash needs, and how the company finances research, commercialization, and any potential debt repayment. Understanding the size, structure, and intended use of these proceeds is central to assessing how Alvotech stock now fits into a diversified portfolio.

Alvotech’s capital raise comes after a mixed stretch for investors, with the share price at $3.92, a 30 day share price return of 17.37% and a one year total shareholder return that declined 57.06%. This suggests recent momentum contrasts with a weaker longer term record.

If this funding round has you thinking about where else capital might find opportunities in healthcare and biotech, it could be worth scanning a wider set of healthcare focused AI leaders through the 38 healthcare AI stocks

With Alvotech trading at $3.92, a recent 30 day gain of 17.37% sits beside a one year total return that declined 57.06%. This raises the question of whether the stock is still trading at a discount or if the market is already pricing in future growth.

Most Popular Narrative: 71.7% Undervalued

Compared to Alvotech’s last close at $3.92, the most followed narrative anchors on a fair value of $13.83 per share, built on detailed long term forecasts.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step-change in topline revenue once approvals are secured.

Curious what underpins that gap between price and fair value? The narrative leans on expectations of faster revenue growth, higher margins and a future earnings multiple that assumes meaningful execution.

Result: Fair Value of $13.83 (UNDERVALUED)

However, that upside story for Alvotech hinges on regulatory approvals arriving as planned and on price competition not eroding margins to the point where those forecasts no longer stack up.

Next Steps

Looking for more investment ideas beyond Alvotech?

If Alvotech has sharpened your focus on opportunity and risk, do not stop here. Widen your search with targeted stock ideas built from the Simply Wall Street Screener.

• Spot potential mispriced opportunities early by scanning a curated set of screener containing 19 high quality undiscovered gems before they move onto everyone else's radar.
• Build a sturdier core for your portfolio by assessing companies in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial strength with cleaner balance sheets.
• Dial down volatility and focus on resilience by reviewing stocks in the 66 resilient stocks with low risk scores that many investors may be overlooking today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.